EyePoint Pharmaceuticals

Press Releases

pSivida pancreatic cancer results released
Jan 29, 2008
pSivida pancreatic cancer results released Boston, MA and Perth, Australia (January 29, 2008) – pSivida Limited (NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced the results of the Phase IIa clinical trial of BrachySilTM for the treatment of advanced, inoperable pancreatic cancer presented at the
BrachySil in Pancreatic Cancer Study Results to be presented at the ASCO Gastrointestinal Cancers Symposium
Jan 23, 2008
BrachySil in Pancreatic Cancer Study Results to be presented at the ASCO Gastrointestinal Cancers Symposium Boston, MA and Perth, Australia (January 23, 2008) – pSivida Limited (NASDAQ: PSDV, ASX: PSD, FF: PSI), a global drug delivery company, today announced that the final results of the recently
pSivida sells pSiNutria to Intrinsiq(UK)
Jan 21, 2008
pSivida sells pSiNutria to Intrinsiq(UK) Boston, MA and Perth, Australia (January 21, 2008) – pSivida Limited (NASDAQ: PSDV, ASX: PSD, FF: PSI), a global drug delivery company, and Intrinsiq Materials Cayman Limited today announced that the assets of pSiNutria Limited, a wholly owned subsidiary of
Displaying 301 - 303 of 303
EyePoint Pharmaceuticals